Drug Trial Radar · NCT03466268
Study to Evaluate the Safety and Anti-tumor Activity of SCC244
Last checked: Nov 20, 2026Latest source record: Oct 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Sep 14, 2017
Primary completion
Jan 9, 2023
Study completion Jan 9, 2023
Sponsor
- Lead sponsor
- Haihe Biopharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 15, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluates the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of SCC244 in patients with advanced solid tumors with c-Met Alterations.
Conditions
- Advanced Solid Tumor
Interventions
Gumarontinib TabletsDrug
Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLT(Dose limit toxity)Time frame: 35 days
- MTD(Max tolerance does)Time frame: 35 days
- BED(Biological effective dose)Time frame: 35 days
- ORR(Objective response rate)Time frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Guangdong General Hospital
Guangzhou, Guangzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.